| PATENT ASSIGNEE'S COUNTRY | Germany |
| UPDATE | 07.00 |
| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | 04.07.00 |
| PATENT TITLE |
Use of 2-methylamino-2-phenylcyclohexanone for the treatment of bacterial infections |
| PATENT ABSTRACT | This invention relates to the use of 2-methylamino-2-phenylcyclohexanone and of pharmaceuticals which contain this active agent in combination with physiologically acceptable solid or liquid supporting materials or diluents for treating bacterial, fungal, virus or protozoan infections as well as for immunomodulation. |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | 15.10.96 |
| PATENT FOREIGN APPLICATION PRIORITY DATA | This data is not available for free |
| PATENT REFERENCES CITED |
Cascorbi et al 120 CA 98635e 1994. Pauli et al 120 CA:156043y 1994. Cascorbi, Ingolf et al., "Effects of heterogenous Set of Xenobiotics on Growth and Plasma Membranes of Mammalian and Fungal Cell Cultures," Ectoxicology and Environmental Safety, 26, 113-126 (1993). |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
We claim: 1. A method of treating a patient having a bacterial infection, comprising: administering to the patient a pharmacologically effective dosage of unsubstituted 2-methylamino-2-phenyl-cyclohexanone (MPCH) or its physiologically tolerable salts. 2. A method of treating a patient as set forth in claim 1, wherein the infection is a mycoplasmal infection. |
| PATENT DESCRIPTION |
FIELD OF INVENTION This invention relates to the use of 2-methylamino-2-phenylcyclohexanone for treating bacterial infections. BACKGROUND OF INVENTION A great number of pharmaceutic agents is used in today's medical practice to treat infections. These infections quite frequently impair the immunological system while a weakened immunological system, on the other hand, attracts infections. As infections are frequently characterized by an accelerated progress of the disease because pathogens multiply exponentially, it is desirable to have therapeutic agents on hand that are suited for initial medication due to their wide activity spectrum. This requirement is currently met only to a limited extent with regard to bacterial infections. Most bacterial infections can be treated with .beta.-lactam antibiotics like, for example, penicillines or cephalosporines. However, those antibiotics can not be used to treat infections caused by certain species of bacteria like Legionella or Mycoplasma. So far, only tetracyclines or macrolids are used to treat infections caused by these bacteria. Thus, the choice of antibiotics which can be used as therapeutics in these cases is very limited. Tetracyclines can also exhibit severe side effects like, for example, phototoxicity or catabolic effects. Other problems occuring with the frequent use of lactams are the increasing number of resistant bacterial strains isolated as well as an increasing number of patients which are allergic against .beta.-lactam antibiotics. SUMMARY OF INVENTION It is therefore a problem to be solved by this invention to provide an agent that is suited for treating a great number of infections caused by bacteria. This agent should be characterized by low toxicity, good tolerability, and a wide therapeutic spectrum. The present invention solves this problem by using 2-methylamino-2-phenylcyclohexanone or its physiologically tolerable salts for the treatment of bacterial infections. DETAILED DESCRIPTION OF INVENTION It was found, surprisingly, that 2-methylamino-2-phenylcyclohexanone is effective against a number of bacterial diseases. 2-methylamino-2-phenylcyclohexanone (MPCH) has been known from U.S. Pat. No. 3,254,124. It describes MPCH as a compound showing cataleptic activity. MPCH has not been used as a pharmaceutical up to now. Another object of the present invention is the use of 2-methylamino-2-phenylcyclohexanone or its physiologically tolerable salts for the production of pharmaceuticals. For this purpose, 2-methylamino-2-phenylcyclohexanone is optionally converted into an acid addition salt, preferably into a salt of a physiologically tolerable acid. Common physiologically tolerable inorganic and organic acids include: hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, malic acid, citric acid, salicylic acid, adipic acid and benzoic acid. Other useable acids are described, for example, in Fortschritte der Arzneimittelforschung, vol. 10, pp 224-225, Birkhauser Verlag Basel and Stuttgart, (1966), and in Journal of Pharmaceutical Sciences, vol. 66, pages 1-5 (1977). The acid addition salts are obtained, as a rule, in a generally known way by mixing the free base or its solutions with the respective acid or its solutions in an organic solvent, for example., a lower alcohol such as methanol, ethanol, n-propanol or isopropanol, or a lower ketone, such as acetone, methylethyl ketone or methyl isobutyl ketone, or an ether such as diethyl ether, tetrahydrofuran, or dioxane. Mixtures of the above solvents can be used to improve crystallization. In addition, physiologically tolerable aqueous solutions of acid addition salts of MPCH can be produced in an aqueous acid solution. The acid addition salts of MPCH can be converted into the free base in a generally known way, e.g. using alkalies or ion exchangers. Other salts can be gained from the free base by reacting it with inorganic or organic acids, especially such acids that are suitable for forming therapeutically applicable salts. These and other salts of the new compound as, for example, its picrate, can also be used for cleaning the free base. For this, the free base is converted into a salt, said salt is separated, and the base released again from the salt. Another object of the present invention are pharmaceuticals for oral, rectal, subcutaneous, intravenous or intramuscular administration which contain MPCH or its acid addition salt as active substance along with the common supporting materials and diluents. The pharmaceuticals of the invention are produced in a known way using the usual solid or liquid supporting materials or diluents and the common adjuvants used in pharmaceutical engineering, and at an appropriate dosage depending on the intended form of administration. Preferred formulations are those forms suitable for oral administration, for example, tablets, film tablets, dragees, capsules, pills, powder, solutions, suspensions, or repository forms. Consideration may also be given to parenteral formulations such as injection solutions. Suppositories represent another form of application. Tablets may be obtained, for example, by intermixing the active substance with known adjuvants, for example, inert diluents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, disintegrating agents which swell rapidly on contact with body fluids and thereby quickly disintegrate the tablets and disperse the medicament such as maize starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talcum and/or materials by which to produce a time release effect, such as carboxyl polymethylene, carboxymethyl cellulose, cellulose acetate phthalate or polyvinyl acetate. Tablets may consist of several layers. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, 15th Edition (1975), Mack Publishing Company, Easton, Pa. 18042. Dragees may be produced accordingly by coating cores manufactured in analogy to tablet manufacture using agents generally applied to dragee coating, for example, polyvinylpyrrolidone or shellac, Arabic gum, talcum, titanium dioxide, or sugar. The coating of the dragee may also consist of several layers in which the adjuvants mentioned in the paragraph on tablets can be used. Solutions or suspensions containing the active agent of the invention may additionally contain flavour-enhancing substances such as saccharin, cyclamate or sugar, or aromatic substances such as vanillin or orange extract. They may also contain suspension-supporting adjuvants such as sodium carboxymethyl cellulose, or preservatives such as p-hydroxybenzoates. Capsules containing active agents may be produced, for example, by mixing the active agent with an inert substrate such as lactose or sorbitol, and encapsulating such mixture in gelatin capsules. Appropriate suppositories may be made by mixing the active substance with the suitable substrates, such as neutral fats or polyethylene glycol |
| PATENT EXAMPLES | This data is not available for free |
| PATENT PHOTOCOPY | Available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |